Current role
Biotechnology · Healthcare
Chief Accounting Officer, CFO, Board Member
2022-01-01–present
Quang X. Pham
Chief Accounting Officer
Cadrenal Therapeutics, Inc. (CVKD)Board Member
Cadrenal Therapeutics, Inc. (CVKD)Equibles does not estimate personal net worth.
Get an email with a short summary when Cadrenal Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get CVKD alertsAbout Quang X. Pham
Quang X. Pham is recorded as Chief Accounting Officer and CFO at Cadrenal Therapeutics, Inc. (CVKD) since May 28, 2026 and Board Member at Cadrenal Therapeutics, Inc. (CVKD) since January 1, 2022. The newest filing on record that lists Quang X. Pham as Board Member at Cadrenal Therapeutics, Inc. (CVKD) is dated August 3, 2026. Cadrenal Therapeutics, Inc. reported in an 8-K filed September 29, 2026 that Quang X. Pham was appointed Class I director, effective September 24, 2026. Cadrenal Therapeutics, Inc. reported in an 8-K filed June 3, 2026 that Quang X. Pham was appointed interim Chief Financial Officer, effective May 28, 2026. Cadrenal Therapeutics, Inc. reported in an 8-K filed June 3, 2026 that Quang X. Pham was appointed interim Principal Accounting Officer, effective May 28, 2026. The proxy statement of Cadrenal Therapeutics, Inc. reports total compensation of $1,909,694 for Quang X. Pham in fiscal 2025, including a base salary of $751,275. Disclosed compensation is on record for 3 fiscal years. Cadrenal Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Cadrenal Therapeutics, Inc. includes John P. Sharp (CFO), Matthew K. Szot (CFO), Jeffrey Cole (COO) and 7 others.
“The following individual was elected as a Class I director, to serve until the Company’s 2029 annual meeting of stockholders and until his successor has been duly elected and qualified with the following votes:”
“Effective immediately after Mr. Szot’s termination, the Company appointed Quang X. Pham, its Chief Executive Officer, as interim Chief Financial Officer and interim Principal Accounting Officer, to serve until a permanent Chief Financial Officer is appointed.”
Affiliation history
-
Current
2026-05-28–present
-
Current
2026-05-28–present
-
Current
2022-01-01–present
Last confirmed August 3, 2026
Company network
Leadership on record at Cadrenal Therapeutics, Inc.
- John P. Sharp CFO
- Matthew K. Szot CFO
- Jeffrey Cole COO
- Class I Directors Board Member
- Glynn Wilson Board Member
- John Murphy Board Member
- Lee Golden Board Member
- Lee Scott Golden, M.D. Board Member
- Robert Lisicki Board Member
- Steven Zelenkofske Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Cadrenal Therapeutics, Inc. (CVKD) | Chief Executive Officer | $751,275 | $1,909,694 |
| 2024 | Cadrenal Therapeutics, Inc. (CVKD) | Chief Executive Officer | $708,750 | $1,223,381 |
| 2023 | Cadrenal Therapeutics, Inc. (CVKD) | Chief Executive Officer | $662,500 | $967,000 |